Secondly, considering the promoting effect of SCD1 and FADS2 on breast cancer development, how to combine these inhibitors to promote the therapeutic effect of existing chemotherapy drugs is a question worth exploring. This evidence concerns the gene FADS2 and breast carcinoma.